

## ORIGINAL ARTICLE

## Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients

MJ McCarthy<sup>1,2,3</sup>, H Wei<sup>1,2,3</sup>, Z Marnoy<sup>1,2,3</sup>, RM Darvish<sup>2,3</sup>, DL McPhie<sup>4</sup>, BM Cohen<sup>4</sup> and DK Welsh<sup>1,2,3</sup>

Bipolar disorder (BD) is associated with abnormal circadian rhythms. In treatment responsive BD patients, lithium (Li) stabilizes mood and reduces suicide risk. Li also affects circadian rhythms and expression of 'clock genes' that control them. However, the extent to which BD, Li and the circadian clock share common biological mechanisms is unknown, and there have been few direct measurements of clock gene function in samples from BD patients. Hence, the role of clock genes in BD and Li treatment remains unclear. Skin fibroblasts from BD patients ( $N=19$ ) or healthy controls ( $N=19$ ) were transduced with *Per2::luc*, a rhythmically expressed, bioluminescent circadian clock reporter gene, and rhythms were measured for 5 consecutive days. Rhythm amplitude and period were compared between BD cases and controls with and without Li. Baseline period was longer in BD cases than in controls. Li 1 mM increased amplitude in controls by 36%, but failed to do so in BD cases. Li 10 mM lengthened period in both BD cases and controls. Analysis of clock gene variants revealed that *PER3* and *RORA* genotype predicted period lengthening by Li, whereas *GSK3 $\beta$*  genotype predicted rhythm effects of Li, specifically among BD cases. Analysis of BD cases by clinical history revealed that cells from past suicide attempters were more likely to show period lengthening with Li 1 mM. Finally, Li enhanced the resynchronization of damped rhythms, suggesting a mechanism by which Li could act therapeutically in BD. Our work suggests that the circadian clock's response to Li may be relevant to molecular pathology of BD.

*Translational Psychiatry* (2013) **3**, e318; doi:10.1038/tp.2013.90; published online 22 October 2013

**Keywords:** bipolar disorder; circadian rhythm; gene expression; lithium

## INTRODUCTION

Bipolar disorder (BD) is a psychiatric illness characterized by disabling episodes of depression and mania that greatly increase the risk of suicide.<sup>1</sup> The biological origins of BD are poorly characterized, but heritability is estimated to be 0.85, suggesting a genetic etiology.<sup>2</sup> Disturbances in sleep and activity are common in BD, leading to the hypothesis that circadian rhythm disruption is an essential feature of the illness (as reviewed in McCarthy and Welsh<sup>3</sup>). The cellular clock comprises ~20 'clock genes' that form transcriptional-translational feedback loops to maintain ~24 h cycles of gene expression and downstream processes.<sup>4</sup> Variants in clock genes have been associated with BD, major depression and seasonal affective disorder.<sup>3</sup> Functional features of the molecular clock are defined by the transcriptional activity of CLOCK/BMAL1 heterodimers that stimulate gene expression through E-box elements in the promoters of *PER1/2/3* and *CRY1/2* genes, with subsequent feedback inhibition by CRY and PER proteins. In the forebrain, NPAS2 may substitute for CLOCK.<sup>5,6</sup> Secondary loops (e.g. RORA/B/C, REV-ERB $\alpha$ ), and post-translational modifications by casein kinases 1 $\delta/\epsilon$  (encoded from CSNK1D/E) and glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) regulate core loop functions, through alterations in protein stability and nuclear compartmentalization.<sup>7</sup> Accordingly, inhibition of GSK3 $\beta$  increases amplitude and shortens period of gene expression rhythms.<sup>8–10</sup>

The mood stabilizer lithium (Li) often improves depression and mania, reduces suicide risk and normalizes daily rhythms in BD, but BD is heterogeneous, with Li-responsive and non-responsive subtypes that may differ in important ways. Among its molecular targets, Li inhibits GSK3 $\beta$ ,<sup>11</sup> a feature of the drug that may account

for the effects on both mood and the clock.<sup>12</sup> Indeed, some studies have identified genetic variants in GSK3 $\beta$ ,<sup>13,14</sup> (but see references 15 and 16), or clock gene substrates of GSK3 $\beta$  (e.g. REV-ERB $\alpha$ ) that predict clinical response to Li.<sup>17,18</sup> Li increases the amplitude of *PER2* rhythms in cells and tissue slices,<sup>10,19,20</sup> a feature of the drug that may bolster weak rhythms in some cells. Unlike selective GSK3 $\beta$  inhibitors, Li lengthens the period of behavioral rhythms,<sup>21–23</sup> a paradox that could indicate the presence of additional Li targets within the clock network. However, no study has adequately examined the connection between Li and circadian clock function in cells from BD patients. Therefore, it is unknown if Li affects rhythms distinctly in BD. The finding that fibroblasts and neurons have cell autonomous molecular clocks operating through similar mechanisms<sup>24</sup> suggests that this question is amenable to study in skin fibroblasts from BD patients.<sup>25</sup>

Our principal hypothesis was that clock gene rhythms and their response to Li would differ in cells from BD patients compared to controls. As secondary hypotheses, we investigated whether clock gene variants and clinical subtypes of BD were associated with differences in rhythms. Supporting our hypotheses, we report that cells from BD patients have longer circadian rhythm periods, and show significant differences in response to Li.

## METHODS

*Per2::luc* reporter

The *Per2::luc* lentiviral reporter gene was provided by Andrew Liu (University of Memphis), and has been described previously.<sup>24</sup> All experiments used  $\sim 1 \times 10^7$  infectious units/plate. Transduction efficiency was estimated to be ~80–100%.

<sup>1</sup>Psychiatry Service, Veterans Affairs San Diego Healthcare System, University of California, San Diego, CA, USA; <sup>2</sup>Department of Psychiatry, University of California, San Diego, CA, USA; <sup>3</sup>Center for Chronobiology, University of California, San Diego, CA, USA and <sup>4</sup>Harvard McLean Hospital, Belmont, MA, USA. Correspondence: Dr MJ McCarthy, Psychiatry Service, Veterans Affairs San Diego Healthcare System, University of California, 3350 La Jolla Village Drive, MC 116A, San Diego, 92161 CA, USA.

E-mail: mmcCarthy@ucsd.edu

Received 22 August 2013; accepted 8 September 2013

## Drugs

Li chloride was purchased from Sigma. Stock Li solutions were made from sterile water at a concentration of 1 M and used to make the appropriate drug-containing cell culture media.

## Human subjects and cell lines

Subjects 18–65 years old were recruited from McLean Hospital (cases) and the surrounding community (healthy controls). BD cases were typically identified while inpatients on a psychiatric unit. All subjects provided informed consent and were paid to participate. Subjects were evaluated with a structured interview (SCID-Mini for DSM-IV) to establish diagnosis. All cases had a primary diagnosis of BD type I. Clinical features including age of onset, psychiatric family history, dysphoric/euphoric mania, past suicide attempts (PSA), alcohol/substance use history were extracted from the diagnostic interview. Most of the BD patients were on multiple psychotropic medications (mean 3.3). Medications at the time of biopsy were recorded (Supplementary Table S1), but details regarding past medication trials and treatment response were not available. Subjects were excluded if they were medically ill or had a history of adverse events with skin biopsies. Age-matched controls were excluded for any psychiatric diagnosis, or use of psychotropic medication.

Fibroblast cell lines were established from skin biopsies from the buttock.<sup>26</sup> De-identified cell lines were subsequently sent to a collaborating laboratory for culture and analysis. At the time of experiments, cell lines had been passaged 3–10 times. Case-control matching was maintained during cell culture procedures and experiments.

## Cell culture and luminometry

For reporter gene assays, cells were grown to confluence in 100-mm plates in standard culture media [DMEM with 10% fetal bovine serum (FBS), glutamine and antibiotics (penicillin, streptomycin and amphotericin)]. After 2 days, cells were dissociated with trypsin, and ~10% of each culture was transferred into one of six identical 35-mm plates (duplicates of vehicle, Li 1 mM and Li 10 mM) and stabilized for 48 h. Afterwards, transduction with the *Per2::luc* construct proceeded over 48 h as cells were grown to confluence (~1.2 × 10<sup>6</sup> cells/plate). Immediately before luminometer assay, growth medium was replaced with HEPES-buffered, serum-free recording media containing 1 mM luciferin (Biosynth International, Staad, Switzerland) as described previously.<sup>27</sup> This procedure was sufficient to synchronize *Per2::luc* rhythms without serum shock. For experiments with Li (1 or 10 mM), drug was continuously present in the growth medium, starting 48 h before recording, and throughout the recording period for a total exposure of ~7 days.

Rhythm measurements were conducted in 35 mm culture plates as previously described<sup>28</sup> using a 32-well luminometer (Actimetrics, Wilmette, IL, USA). Photoemissions were measured from duplicate plates of each sample for 70 s, every 10 min for ~5 days. Temperature was maintained at 35 °C.

## Gene expression

For analyses of *BMAL1*, *CLOCK* and *NPAS2* expression, duplicate cultures (N = 7 control, 10 BD) were grown in six-well plates. Thirty-six hours prior to collection, the medium was changed to 1 mM Li or vehicle containing DMEM to synchronize rhythms. Medium was then aspirated, and the plates were frozen at –80 °C. RNA was prepared using a Qiagen (Hilden, Germany) RNeasy kit, following the instructions provided by the manufacturer. Using a high-capacity reverse transcriptase kit, cDNA (~750 ng) was synthesized following the manufacturer's protocol. Taqman RT-PCR was conducted using a Bio-Rad CFX384 thermocycler with primers (Applied Biosystems, Foster City, CA, USA) targeting *BMAL1* (*ARNTL*), *CLOCK*, *NPAS2* and *GAPDH*, a non-rhythmic control gene suitable for circadian rhythm studies.<sup>29</sup> Gene expression was measured against *GAPDH* using the comparative Ct method.<sup>30</sup> Data were normalized to the vehicle-treated control condition.

## DNA preparation and genotyping

DNA was prepared from cells using a Qiagen DNeasy Kit following the manufacturer's protocol. One single-nucleotide polymorphism (SNP) from each of 14 clock genes was selected for study, based on minor allele frequencies that permit examination in small samples, and where possible, an association with a relevant mood phenotype (Table 1). Most genotyping was done using pre-designed Taqman assays (Applied Biosystems). For the

**Table 1.** Clock gene SNPs and MAF in BD cases and controls

Gene	SNP	MAF Cont	MAF BD	Notes
BMAL1	rs2279287	31.6	13.2	Assoc BD, AKA ARNTL <sup>38</sup>
CLOCK	rs1801260	31.6	26.3	Assoc BD and insomnia <sup>32</sup>
CRY1	rs8192440	26.3	28.9	Assoc Li response <sup>18</sup>
CRY2	rs2037311	2.6	2.6	
CSNK1E	rs1534891	13.2	10.5	
GSK3β	rs334558	28.9	28.9	Assoc Li response <sup>13,14</sup>
NPAS2	rs11541353	18.4	23.7	Assoc SAD, AKA S471L <sup>33</sup>
Rev-Erbα	rs2071427	18.4	18.4	Assoc Li response, <sup>18</sup> AKA NR1D1
PER1	rs3027178	15.8	26.3	
PER2	rs56013859	15.8	26.3	Assoc SAD, <sup>33</sup> AKA 10870
PER3	rs228729	36.8	26.3	Assoc BD, <sup>38</sup> tags VNTR
RORA	rs12912233	44.7	39.5	Assoc depression <sup>31</sup>

Abbreviations: Assoc, associated; AKA, also known as; MAF, minor allele frequency; SAD, seasonal affective disorder; SNP, single-nucleotide polymorphism; VNTR, variable number tandem repeat. In some instances, past illness associations and reference are indicated. Also known as (AKA) indicates alternate name for SNP or gene.

*PER2* SNP rs56013859, a custom Taqman assay was purchased using published sequence.<sup>35</sup> PCR reactions were conducted as described above.

## Data analysis

For each cell line, luminometry data were averaged and fitted to a damped sine curve by the least squares method using commercial software (Lumicycle Analysis, Actimetrics). To limit variability, the first 0.6 days were excluded from analysis. Data were filtered using moving average background subtraction. Rhythm parameters were defined as period, amplitude and goodness of fit as an index of rhythm robustness. Phase was correlated to period and for this reason, was not considered separately. For two-way analyses of rhythms, parameters were analyzed separately using an unpaired, two-tailed *t*-test or Mann–Whitney *U*-test. For analyses of Li-induced changes in rhythms, a two-way analysis of variance with repeated measures was conducted for each parameter. Correlations were established using Pearson's test. All analyses were conducted using GraphPad Prism version 5.0 (San Diego, CA, USA). *P*-values < 0.05 were employed as the threshold for significance in primary analyses. The Benjamini–Hochberg correction for multiple comparisons employing a false discovery rate of 0.05<sup>36</sup> was applied to secondary analyses using publicly available software (Q-Value). After this correction, *P*-values < 0.001 remained significant. *P*-values < 0.05 that fell short of significance after false discovery rate correction were reported as nominally significant.


## RESULTS

### Baseline rhythm parameters

Robust oscillations in *Per2::luc* gene expression were present in all cell lines (goodness of fit > 80%). Consistent with previous reports of peripheral cell cultures, rhythms were detectable in all cultures for > 5 days before eventual rhythm damping, likely reflecting desynchronization.<sup>37</sup> In our primary analysis examining rhythm parameters among BD cases and controls, rhythm amplitude was similar between groups. However, period was longer by ~25 min in BD cells compared with controls (controls 25.1 ± 0.2 h vs BD 25.5 ± 0.2 h, mean ± s.e.m., *U* = 104.5, *P* < 0.03, Supplementary Table S2).

### Li treatment and rhythms

Li is chronically dosed in BD patients to serum concentrations of 0.5–1.0 mM, whereas past *in vitro* studies have used Li concentrations



**Figure 1.** Fibroblasts from BD patients have an attenuated response to Li. Vehicle, Li 1 mM or Li 10 mM was included in the growth medium for 48 h prior to, and continuously during 5 days of recording. Rhythmic *Per2::luc* expression was measured as counts per second (cps) with baseline subtraction. (a) Amplitude increased in cells from control ( $N = 19$ ,  $P < 0.01$ ), but not BD ( $N = 19$ ,  $P = 0.32$ ) subjects after Li 1 mM (error bars indicate 95% confidence intervals). (b) There was a non-significant trend toward greater period lengthening in controls compared with BD cells after Li 10 mM (error bars indicate 95% confidence intervals). Representative vehicle-treated (black) and Li-treated (red) rhythm traces are shown for representative control and BD cell lines at 1 mM (c, d) and 10 mM (e, f).

> 10 mM.<sup>7,10</sup> In order to investigate both conditions, we used Li concentrations of 1 mM and 10 mM. While there was heterogeneity among individual samples, Li 1 mM on average did not lengthen period in either control or BD cells. Li 1 mM increased amplitude by ~36% in control cells (31.7 vehicle vs 43.2 Li,  $P < 0.01$ , Figure 1a), but failed to significantly increase amplitude in BD cells (31.7 vehicle vs 35.5 Li,  $P = 0.38$ , Supplementary Table S3, Figure 1b).

In agreement with previous studies, Li 10 mM caused period lengthening in control and BD cells (Supplementary Table S4, Figures 1c and d), with a trend toward greater period lengthening in controls compared to BD (0.9 h control vs 0.4 h BD,  $P = 0.09$ ). In contrast to the lower concentration, Li 10 mM increased the mean *Per2::luc* signal, but significantly suppressed amplitude ( $P < 0.0001$ ) after subtracting the non-rhythmic component. This amplitude reduction was similar between groups, with decreases of 27% and 37% for controls and BD respectively. There was no significant drug  $\times$  genotype interaction.


#### Analysis of CLOCK, BMAL1 and NPAS2 expression

Rhythmic expression of PER2 is driven by heterodimeric CLOCK:BMAL1 or CLOCK:NPAS2 complexes binding to E-box promoter elements. Like *PER2*, *BMAL1* and *NPAS2* expression is rhythmic, but with a different phase, peaking ~12 h earlier than *PER2*. While *CLOCK* has an important role in mediating *PER2* rhythms, its expression can be rhythmic or constitutive depending on the tissue, and rhythmic expression is not essential for *CLOCK*'s

function.<sup>34</sup> In an initial examination of the molecular mechanisms by which amplitude was increased after treatment with Li 1 mM in control but not BD cells, we measured expression of *BMAL1*, *CLOCK* and *NPAS2* in fibroblasts 36 h after a synchronizing medium change, with or without Li 1 mM added to the medium. Based on the results of *Per2::luc* experiments, this is a time when peak expression of all three genes is expected. However, at this time point there were no differences in *BMAL1*, *CLOCK* or *NPAS2* expression between BD cases and controls either at baseline or after Li treatment (Supplementary Table S5). Because the heterodimer is the functional unit for the relevant gene products, and *CLOCK* and *NPAS2* compete for *BMAL1* binding, the ratios of *CLOCK/BMAL1*, *CLOCK/NPAS2* and *NPAS2/BMAL1* were each calculated (Supplementary Table S6). Li significantly decreased the ratio of *CLOCK/NPAS2* ( $P = 0.02$ ), and increased the ratio of *NPAS2/BMAL1* ( $P = 0.01$ ), but these effects were similar among BD cases and controls. Therefore, although Li may increase the relative contribution of *NPAS2* to *PER2* regulation, we found no changes in peak *BMAL1*, *CLOCK*, or *NPAS2* expression that might explain why *Per2::luc* rhythm amplitude was increased by Li 1 mM in control, but not BD cells.

#### Genetic variation in the clock and Li

As a secondary analysis, we examined clock gene variants as predictors of Li-induced rhythm changes. Minor allele frequency and overall burden of variant clock gene alleles did not



**Figure 2.** Rhythm modulation by Li is associated with clock gene variants. **(a)** Period lengthening after Li 1 mM for *RORA* rs12912233 homozygous common (T/T), heterozygous (C/T) and homozygous variant (C/C) genotypes [ $N = 5/11/3$  (controls),  $N = 7/9/3$  (BD),  $P < 0.05$ ]. **(b)** Period lengthening after Li 10 mM for *PER3* rs228729 homozygous common (T/T), heterozygous (T/C) and homozygous variant (C/C) genotypes [ $N = 6/12/1$  (controls),  $N = 11/6/2$  (BD),  $P < 0.001$ ]. In both cases **(a,b)**, genotype effects were significant regardless of diagnosis so BD cases and controls have been combined. **(c)** Amplitude increase after Li 1 mM among *GSK3β* – 50T/C homozygous common (T/T) and rare variant carriers (T/C and C/C). Two-way ANOVA revealed a significant genotype  $\times$  diagnosis interaction ( $P < 0.05$ ), but no significant difference between genotypes or diagnoses alone. **(d)** Period lengthening after Li 10 mM. Two-way ANOVA revealed effect of BD ( $P < 0.05$ ), and significant genotype  $\times$  diagnosis interaction ( $P < 0.001$ ). For homozygous common/heterozygous/homozygous variant genotypes,  $N = 8/11/0$  (controls) and  $N = 9/9/1$  (BD), respectively. Error bars indicate s.e.m.

significantly differ between BD cases and controls (Table 1). However, when period and amplitude were examined as quantitative traits under baseline and Li-treated conditions, two of these variants were nominally associated with period lengthening, independent of BD diagnosis (*RORA* rs12912233, and *PER3* rs228729, Figures 2a and b). Homozygotes for the common T allele in *RORA* showed period lengthening with Li 1 mM, but heterozygous or homozygous carriers of the variant C allele did not ( $P < 0.05$ ). Carriers of the *PER3* variant C allele were more sensitive to the effect of Li 10 mM in an allelic copy number-dependent manner ( $P < 0.001$ ). Interestingly, the *RORA* SNP has previously been associated with depression traits by genome-wide association study,<sup>31</sup> and the *PER3* variant has been associated with BD.<sup>38</sup>


*GSK3β* SNP rs334558 (– 50T/C) has previously been associated with clinical response to Li in both BD and major depression.<sup>13,14</sup> With respect to rhythms, there were nominally significant interactions ( $P < 0.05$ ) between *GSK3β* genotype and diagnosis: cells from BD subjects carrying the variant C allele showed increased amplitude in the presence of Li 1 mM, similar to the controls of either genotype, but BD cells homozygous for the common T allele did not (Figure 2c). *GSK3β* genotype also predicted period lengthening by Li 10 mM, but again only in BD cell lines, with a main effect of diagnosis ( $P < 0.05$ ), and a significant diagnosis  $\times$  genotype interaction ( $P < 0.001$ ). Control cells demonstrated period lengthening regardless of *GSK3β* genotype, BD cells with the homozygous T/T genotype showed no change in period, and cells with C/C or T/C *GSK3β* genotypes showed period lengthening, similar to controls (Figure 2d). Period and amplitude were not correlated in the study population as a whole, suggesting that this pattern of genetic association reflects non-redundant contributions of *GSK3β* to amplitude and period effects.

#### Clinical subtype associations

Clinical features have been used to predict Li response and suicide risk in BD.<sup>39</sup> We conducted secondary analyses of the rhythm data

to assess differences among BD sub-phenotypes. Neither PSA, comorbid alcohol use disorder/substance use disorders, nor family history of BD in first degree relatives were associated with any difference in baseline rhythm parameters. Subjects with only euphoric manias (compared with sometimes/always dysphoric) had slightly less rhythm robustness (goodness of fit: 85% dysphoric, 78% euphoric,  $P < 0.05$ ), but did not differ in period or amplitude (Supplementary Table S7). Female sex was nominally associated with exclusively euphoric mania, and negatively associated with rhythm robustness (goodness of fit: female 75.7% vs male 84.8%,  $P < 0.01$ ). Age, age of BD onset and illness duration did not correlate with any rhythm parameter. Among controls, age and sex did not correlate with any rhythm parameter.

Using the phenotypic and demographic variables above, we also examined the clock gene response to Li in BD cells by clinical features. Unlike controls and BD subjects considered collectively, BD subjects with a history of PSA demonstrated nominally significant period lengthening after treatment with Li 1 mM (Figure 3a). Under the same conditions, there was a trend towards amplitude increases in the PSA positive group, but it was not statistically significant (Figure 3b). However, when suicide history was assessed as a quantitative measure (number of PSAs), there were nominally significant correlations ( $P < 0.05$ ) between PSA and period lengthening by Li 1 mM ( $r = 0.47$ ,  $P < 0.05$ , Figure 3c). The correlation between PSA and amplitude increase by Li 1 mM was also significant ( $r = 0.50$ ,  $P < 0.05$ , Figure 3d), but was strongly affected by a single data point with 4 PSAs, and was no longer significant when this subject was excluded. Comorbid alcohol use disorder/substance use disorder, family history or demographic variables were not associated with any changes in rhythm parameters after treatment with Li 1 mM. With Li 10 mM, amplitude was nominally higher in the dysphoric mania BD subgroup compared with those with euphoric mania only (23.4 vs 15.2 relative units,  $P < 0.05$ ). There were no further BD subgroup differences in response to Li 10 mM when considering alcohol use disorder/substance use disorder, PSA, family history or age/sex.



**Figure 3.** Suicide in BD is associated with period lengthening and amplitude increase after Li 1 mM. When measured categorically, BD patients with a history of suicide were more sensitive to (a) period lengthening, but not (b) amplitude increase after treatment with Li 1 mM. *P*-values indicate the results of 1-way ANOVA with *N* = 6 PSA positive/13 PSA negative/19 controls. Error bars indicate s.e.m. When measured quantitatively, suicide history is significantly correlated with both (c) period lengthening and (d) amplitude increase after Li 1 mM.

#### Li augments rhythm resynchronization

The effect of Li on amplitude suggests that the drug may bolster weak or failing rhythms in vulnerable cell populations, by improving rhythm amplitude. We tested this hypothesis in fibroblasts from control and BD subjects. Rhythms in untreated cells were allowed to damp over 5 days, and were then subjected to medium change, a stimulus commonly used to resynchronize rhythms in cell cultures. The medium change partially restored rhythms in the absence of Li, but the resulting rhythm was typically weak with low amplitude and period exceeding the duration typically considered circadian (>30 h), consistent with poor synchronization among cells. When Li 10 mM was included in the medium, rhythms were more robustly restored, more closely resembling the initial signal, with higher amplitude and period closer to 24 h (Figures 4a–c). Statistical analysis revealed significant medium change  $\times$  drug interactions for both amplitude ( $P < 0.04$ , Figure 4a) and period ( $P < 0.0001$ , Figure 4b), favoring rhythm restoration in Li-treated cells. The augmentation of rhythms by Li was similar in BD cases and controls ( $N = 5$  Li treated of each), suggesting that despite the relative insensitivity of BD cells to Li compared with controls when rhythms are robust, BD cells remain Li sensitive when synchronization and/or amplitudes are weak and that therapeutic benefits of Li related to clock function in BD may be preferentially engaged when rhythms are attenuated.

## DISCUSSION

### Overview

Evidence from a range of sources supports the notion that the biological clock is perturbed in BD, and that Li restores rhythms.<sup>3</sup> However, definitive demonstration of cellular clock abnormalities in BD has proven elusive. We have shown in fibroblasts from BD patients that the cellular clock is functional, but generally runs slow, with a longer period, and is less sensitive to Li modulation. Among BD cases, variability in the rhythm response to Li is associated with clinical and genetic factors already known to be associated with clinical outcomes among BD patients. Although we do not know the clinical Li response history of our BD subjects, and cannot determine causality from these observations, the


association of rhythm parameters with GSK3 $\beta$ , a known genetic predictor of response, suggests that some of Li's therapeutic mechanisms may overlap with elements of the cellular clock, and could form the basis of a future biomarker for BD and/or Li response.

### Effect of Li on rhythms

The period lengthening effect of Li on circadian rhythms is well established,<sup>21–23</sup> and recent studies using bioluminescent cellular reporters have shown that Li increases amplitude.<sup>10,19,20</sup> Our results generally agree with past reports, and extend these findings to include clinical samples from BD patients. We have also shown that the relative contribution of CLOCK and NPAS2 in governing rhythms may be affected by Li, but occurs at concentrations below those required to alter period, and is unrelated to the differential modulation of amplitude observed in BD cases. Therefore, this level of transcriptional regulation by Li may be unimportant to PER2 regulation, but could conceivably influence the expression of other rhythmic genes (that is PER1/3, CRY1/2). However, our work also underscores the heterogeneity among individual responses, and differs in some respects from past work. Specifically, our results show that at higher concentrations of Li, the effect on amplitude is complex with greater overall expression of *Per2::luc*, but suppression of the rhythmic component after background subtraction. Our observations in human and mouse cells indicate these differences are explained to some extent by chronic vs acute Li dosing, and species. Of particular importance to BD, there may be important differences between neurons and fibroblasts, with indications that fibroblasts require higher concentrations of Li to influence rhythms.<sup>10</sup>

### Rhythm differences between BD cases and controls

We found longer circadian periods of *Per2::luc* rhythms in BD compared with controls. Long free running periods cause a delay in activity onset. Hence, this finding could point to a genetic basis for the nocturnal preference reported in BD patients who may experience the drive for peak activity later in the day.<sup>40</sup> A previous study of BD fibroblasts using PCR-based measurements did not



**Figure 4.** Li improves rhythm resynchronization. Cellular rhythms ( $N=10$  each BD and control) were measured without treatment until damped (dashed line, day 1–5 in panel **a**). In order to restore rhythms, medium change with Li 10 mM (red) or vehicle (black) was performed on day 5.5 (arrow in panel **a**). Omitting the signal artifact associated with media change, rhythms were then measured another 2 days (solid line in panel **a**). After media change, Li-treated cells had **(b)** significantly higher rhythm amplitudes ( $P<0.05$ ), and **(c)** lower periods ( $P<0.001$ ) compared with vehicle-treated cells. Following media change, period in Li-treated cells was in the circadian range ( $23.1 \pm 0.5$  h (Ave  $\pm$  s.e.m.)); whereas period in the vehicle-treated cells was not ( $31.1 \pm 1.9$  h (Ave  $\pm$  s.e.m.)).

find differences in circadian period,<sup>41</sup> but the *Per2::luc* method we used measures rhythms at a higher sampling density, and therefore the discordant results may be due to the increased sensitivity of our technique compared with older methods. The same study did report reduced amplitudes of BMAL1, Rev-Erb $\alpha$  and DBP rhythms.<sup>41</sup> Similarly, amplitude abnormalities in behavior have been reported in actigraphy studies of euthymic BD patients.<sup>42</sup> We did not find evidence of lower *Per2::luc* amplitude

at baseline in BD, and did not measure amplitude of BMAL1, Rev-Erb $\alpha$  or DBP rhythms. However, we report that Li increases *Per2::luc* amplitude at therapeutic concentrations, consistent with the idea that Li could reverse putative rhythm defects reported by others.

In general, cells from BD patients were less responsive to Li's modulation of amplitude (and perhaps period) than were controls. Taken together, these findings could indicate that the clock in BD is not particularly impaired at baseline, but may be less flexible, and not as responsive to conditions that would normally shift the clock. This finding might be relevant to observations that disruptions to light–dark or sleep schedules can trigger mood episodes in individuals susceptible to BD.<sup>43</sup> Alternatively, past exposure to Li and/or other psychotropic medications may have had lasting effects on the Li sensitivity of cellular rhythms. As BD cell line donors were more likely to be exposed to medication than controls, this could, in principle, explain the differences between groups, but requires the presence of a long-lasting mechanism to explain the result after multiple passages of cell culture. To date, no such mechanism has been described. Regardless of the mechanism, when rhythms were attenuated by damping, both BD and control cells showed a similar degree of improvement in rhythms after Li. Interestingly, valproic acid has been reported to increase rhythm amplitude.<sup>19</sup> Although this drug has not been examined in BD cell lines, the similar amplitude-enhancing effects of Li and valproic acid suggest the possibility of a common circadian mechanism among mood stabilizers. Further, despite the insensitivity of the BD clock to Li, these results suggest that low amplitude clocks may become desynchronized, and benefit from amplitude-enhancing treatments to facilitate resynchronization. This may be relevant to cell populations in the brain that govern mood, some of which express clock genes and/or have circadian oscillators (as reviewed in McCarthy and Welsh<sup>3</sup>). In contrast, the effect of Li on period may worsen the already longer period in BD, further delaying activity onset, and the period effect is prominent only at supratherapeutic concentrations. For these reasons, we hypothesize that any therapeutic effect of Li on the clock is primarily due to modulation of amplitude, and not period.

#### Li-responsive BD and circadian rhythms

BD is commonly divided into Li-responsive and non-responsive types.<sup>44</sup> We do not have data on the clinical Li-responsiveness of the BD patients from which our cells were derived, but we did examine clinical and genetic features previously shown to be associated with Li-responsiveness. Classical Li responders have few comorbid psychiatric diagnoses, a positive family history of BD, and a preponderance of euphoric manias.<sup>39</sup> We did not find clear differences in rhythms across these clinical dimensions. However, genetic factors, including some that predict clinical Li response, were associated with Li-induced changes in rhythms. We have shown previously that expression of clock genes, and genes strongly regulated by the clock are preferentially modulated by Li.<sup>45</sup> Moreover, clinical Li response has been previously associated with genetic variants in the circadian clock, including the  $-50T/C$  SNP in *GSK3 $\beta$* , and Rev-Erb $\alpha$ .<sup>17,18</sup> The  $-50T/C$  SNP is thought to affect the *GSK3 $\beta$*  promoter, with the C allele associated with lower gene expression, perhaps phenocopying the effects of Li inhibition of the enzyme.<sup>18</sup> In the present study, *GSK3 $\beta$*  genotype was associated with amplitude increase in response to Li 1 mM, and also with period lengthening at Li 10 mM, but only in BD cell lines. For both parameters, there was a genotype  $\times$  diagnosis interaction, suggesting that the function of *GSK3 $\beta$*  in rhythm regulation differs in control and BD cells. This finding suggests that *GSK3 $\beta$*  may have a distinctive role in BD, consistent with numerous reports implicating it as a pathogenic factor in the illness.<sup>46–50</sup>

## Functional implications for Li and genetic variation in the clock

In addition to the BD-specific differences associated with GSK3 $\beta$ , we identified two variants in PER3 and RORA that were associated with period length after Li in both BD cases and controls, suggesting these may reflect variation in the clock that is not necessarily pathogenic for BD, but may influence the course of Li treatment. The RORA variant is intronic, with presumptive regulatory function. Of interest, other variants in RORA have been independently associated with anti-depressant response,<sup>51</sup> post-traumatic stress disorder<sup>52</sup> and BD<sup>53</sup> suggesting the RORA gene may be vulnerable in multiple psychiatric conditions. The PER3 variant is in almost perfect linkage disequilibrium with the variable number tandem repeat (VNTR) polymorphism. The VNTR is predicted to alter protein coding sequence of PER3, changing the number of sites available for casein kinase 1 $\epsilon$  phosphorylation.<sup>54</sup> In addition to BD,<sup>55</sup> the VNTR has been associated with diurnal preference, and sleep abnormalities.<sup>56</sup> Therefore, while the effect of this PER3 variant on period in our experiment is similar between BD cases and controls, it too may have effects on illness progression or treatment, especially in the context of therapeutic Li use.

## Suicide and circadian rhythms

Li has been identified as an anti-suicide drug, reducing risk in BD by fivefold.<sup>57</sup> There is evidence that suicidal behavior is genetically transmitted<sup>58,59</sup> and segregates independently of BD.<sup>60</sup> Diurnal variation in suicide has been suggested, with reports of both nighttime<sup>61</sup> and morning peaks in incidence.<sup>62</sup> More consistently, suicides have been shown to have a seasonal pattern with peaks in spring and autumn.<sup>63</sup> A recent study found *PER1* among several downregulated genes in the prefrontal cortex of suicide victims.<sup>64</sup> In this context, it is interesting that our BD subjects with a suicide history were especially sensitive to Li's effects, suggesting that the clock genes may be among those underlying suicide, the most severe pathological feature of BD.

## Study limitations

Peripheral clocks recapitulate central features of cellular clocks in the brain, but tissue specific factors may be important. Furthermore, our study was small, and underpowered to examine clinical and genetic sub-phenotypes in detail. Due to the number of secondary analyses conducted; there is an increased risk of false-positive associations, and replication will be required. Future efforts will be directed toward testing our novel hypotheses in the context of large, well-powered studies that are amenable to detailed analyses.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ACKNOWLEDGMENTS

The authors thank Dost Öngür for his assistance in subject recruitment, and Caroline Nievergelt for providing statistical advice. MJM is supported by a Veterans Affairs Career Development Award (1IK2BX001275). DKW receives support from a Veterans Affairs Merit Award (1I01BX001146), NIMH (R01 MH082945) and NARSAD Young Investigator Award. BC is the recipient of a NARSAD Distinguished Investigator Award. The funders had no role in the analysis, decision to publish or preparation of the manuscript.

## REFERENCES

- 1 Oquendo MA, Currier D, Liu SM, Hasin DS, Grant BF, Blanco C. Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry* 2010; **71**: 902–909.
- 2 McGuffin P, Rijdsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. *Arch Gen Psychiatry* 2003; **60**: 497–502.
- 3 McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders. *J Biol Rhythms* 2012; **27**: 339–352.
- 4 Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. *Nat Rev Genet* 2008; **9**: 764–775.
- 5 Reick M, Garcia JA, Dudley C, McKnight SL. NPAS2: an analog of clock operative in the mammalian forebrain. *Science* 2001; **293**: 506–509.
- 6 DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. *Nat Neurosci* 2007; **10**: 543–545.
- 7 Yin L, Wang J, Klein PS, Lazar MA. Nuclear receptor Rev-erb $\alpha$  is a critical lithium-sensitive component of the circadian clock. *Science* 2006; **311**: 1002–1005.
- 8 Reischl S, Kramer A. Kinases and phosphatases in the mammalian circadian clock. *FEBS Lett* 2011; **585**: 1393–1399.
- 9 Hirota T, Lewis WG, Liu AC, Lee JW, Schultz PG, Kay SA. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3 $\beta$ . *Proc Natl Acad Sci USA* 2008; **105**: 20746–20751.
- 10 Li J, Lu WQ, Beesley S, Loudon AS, Meng QJ. Lithium impacts on the amplitude and period of the molecular circadian clockwork. *PLoS One* 2012; **7**: e33292.
- 11 Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. *Proc Natl Acad Sci USA* 1996; **93**: 8455–8459.
- 12 Iitaka C, Miyazaki K, Akaike T, Ishida N. A role for glycogen synthase kinase-3 $\beta$  in the mammalian circadian clock. *J Biol Chem* 2005; **280**: 29397–29402.
- 13 Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C *et al*. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3- $\beta$  -50 T/C SNP. *Neurosci Lett* 2005; **376**: 51–55.
- 14 Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsaahuridu M, Kirchheiner J *et al*. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3- $\beta$  -50T/C single nucleotide polymorphism. *Biol Psychiatry* 2007; **62**: 1295–1302.
- 15 Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D *et al*. Association study of the INPP1, 5HTT, BDNF, AP-2 $\beta$  and GSK-3 $\beta$  GENE variants and retrospectively scored response to lithium prophylaxis in bipolar disorder. *Neurosci Lett* 2006; **403**: 288–293.
- 16 Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmitrak-Weglarz M *et al*. Association study of the glycogen synthase kinase-3 $\beta$  gene polymorphism with prophylactic lithium response in bipolar patients. *World J Biol Psychiatry* 2006; **7**: 158–161.
- 17 Campos-de-Sousa S, Guindalini C, Tondo L, Munro J, Osborne S, Floris G *et al*. Nuclear receptor rev-erb- $\alpha$  circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder. *J Biol Rhythms* 2010; **25**: 132–137.
- 18 McCarthy MJ, Nievergelt CM, Shekhtman T, Kripke DF, Welsh DK, Kelsoe JR. Functional genetic variation in the Rev-Erb $\alpha$  pathway and lithium response in the treatment of bipolar disorder. *Genes Brain Behav* 2011; **10**: 852–861.
- 19 Johansson AS, Brask J, Owe-Larsson B, Hetta J, Lundkvist GB. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase. *J Biol Rhythms* 2011; **26**: 541–551.
- 20 Osland TM, Ferno J, Havik B, Heuch I, Ruoff P, Laerum OD *et al*. Lithium differentially affects clock gene expression in serum-shocked NIH-3T3 cells. *J Psychopharmacol* 2011; **25**: 924–933.
- 21 Kripke DF, Judd LL, Hubbard B, Janowsky DS, Huey LY. The effect of lithium carbonate on the circadian rhythm of sleep in normal human subjects. *Biol Psychiatry* 1979; **14**: 545–548.
- 22 Kripke DF, Wyborney VG. Lithium slows rat circadian activity rhythms. *Life Sci* 1980; **26**: 1319–1321.
- 23 Welsh DK, Moore-Ede MC. Lithium lengthens circadian period in a diurnal primate, *Saimiri sciureus*. *Biol Psychiatry* 1990; **28**: 117–126.
- 24 Liu AC, Welsh DK, Ko CH, Tran HG, Zhang EE, Priest AA *et al*. Intercellular coupling confers robustness against mutations in the SCN circadian clock network. *Cell* 2007; **129**: 605–616.
- 25 Brown SA, Fleury-Olela F, Nagoshi E, Hauser C, Juge C, Meier CA *et al*. The period length of fibroblast circadian gene expression varies widely among human individuals. *PLoS Biol* 2005; **3**: e338.
- 26 Takashima A. Establishment of fibroblast cultures. *Curr Protoc Cell Biol* 2001, Chapter 2: Unit 2.1.1–2.1.12.
- 27 Yamazaki S, Takahashi JS. Real-time luminescence reporting of circadian gene expression in mammals. *Methods Enzymol* 2005; **393**: 288–301.
- 28 Welsh DK, Imaizumi T, Kay SA. Real-time reporting of circadian-regulated gene expression by luciferase imaging in plants and mammalian cells. *Methods Enzymol* 2005; **393**: 269–288.
- 29 Kosir R, Acimovic J, Golcnik M, Perse M, Majdic G, Fink M *et al*. Determination of reference genes for circadian studies in different tissues and mouse strains. *BMC Mol Biol* 2010; **11**: 60.

- 30 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 2008; **3**: 1101–1108.
- 31 Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S et al. Genome-wide association scan of trait depression. *Biol Psychiatry* 2010; **68**: 811–817.
- 32 Benedetti F, Dall'aspezia S, Fulgosi MC, Lorenzi C, Serretti A, Barbini B et al. Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**: 631–635.
- 33 Partonen T, Treutlein J, Alpman A, Frank J, Johansson C, Depner M et al. Three circadian clock genes *Per2*, *Arntl*, and *Npas2* contribute to winter depression. *Ann Med* 2007; **39**: 229–238.
- 34 Wyse CA, Coogan AN. Impact of aging on diurnal expression patterns of CLOCK and BMAL1 in the mouse brain. *Brain Res* 2010; **1337**: 21–31.
- 35 Kovanen L, Saarikoski ST, Haukka J, Pirkola S, Aromaa A, Lonnqvist J et al. Circadian clock gene polymorphisms in alcohol use disorders and alcohol consumption. *Alcohol Alcohol* 2010; **45**: 303–311.
- 36 Storey JD. A direct approach to false discovery rates. *J Royal Statistic Soc. Series B* 2002; **64**: 479–498.
- 37 Welsh DK, Yoo SH, Liu AC, Takahashi JS, Kay SA. Bioluminescence imaging of individual fibroblasts reveals persistent, independently phased circadian rhythms of clock gene expression. *Curr Biol* 2004; **14**: 2289–2295.
- 38 Nievergelt CM, Kripke DF, Barrett TB, Burg E, Remick RA, Sadovnick AD et al. Suggestive evidence for association of the circadian genes *PERIOD3* and *ARNTL* with bipolar disorder. *Am J Med Genet B Neuropsychiatr Genet* 2006; **141B**: 234–241.
- 39 Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. *J Clin Psychiatry* 2003; **64**(Suppl 5): 53–61.
- 40 Wood J, Birmaher B, Axelson D, Ehmann M, Kalas C, Monk K et al. Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals. *Psychiatry Res* 2009; **166**: 201–209.
- 41 Yang S, Van Dongen HP, Wang K, Berrettini W, Bucan M. Assessment of circadian function in fibroblasts of patients with bipolar disorder. *Mol Psychiatry* 2009; **14**: 143–155.
- 42 Jones SH, Hare DJ, Evershed K. Actigraphic assessment of circadian activity and sleep patterns in bipolar disorder. *Bipolar Disord* 2005; **7**: 176–186.
- 43 Wehr TA. Sleep loss: a preventable cause of mania and other excited states. *J Clin Psychiatry* 1989; **50 Suppl**: 8–16.
- 44 McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. *Pharmacogenomics* 2010; **11**: 1439–1465.
- 45 McCarthy MJ, Nievergelt CM, Kelsoe JR, Welsh DK. A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response. *PLoS One* 2012; **7**: e32091.
- 46 Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. *J Neurosci* 2006; **26**: 9022–9029.
- 47 Gould TD, Einat H, O'Donnell KC, Picchini AM, Schloesser RJ, Manji HK. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. *Neuropsychopharmacology* 2007; **32**: 2173–2183.
- 48 Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. *Biol Psychiatry* 2007; **61**: 240–245.
- 49 Lachman HM, Pedrosa E, Petruolo OA, Cockerham M, Papolos A, Novak T et al. Increase in GSK3beta gene copy number variation in bipolar disorder. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**: 259–265.
- 50 Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C et al. Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. *Neuropsychopharmacology* 2013; **38**: 313–327.
- 51 Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al. A genome-wide association study of citalopram response in major depressive disorder. *Biol Psychiatry* 2010; **67**: 133–138.
- 52 Logue MW, Baldwin G, Guffanti G, Melista E, Wolf EJ, Reardon AF et al. A genome-wide association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha (*RORA*) gene as a significant risk locus. *Mol Psychiatry* 2012; **18**(8): 937–942.
- 53 Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W et al. Genome-wide association study of bipolar disorder in European American and African American individuals. *Mol Psychiatry* 2009; **14**: 755–763.
- 54 Archer SN, Robilliard DL, Skene DJ, Smits M, Williams A, Arendt J et al. A length polymorphism in the circadian clock gene *Per3* is linked to delayed sleep phase syndrome and extreme diurnal preference. *Sleep* 2003; **26**: 413–415.
- 55 Benedetti F, Dall'aspezia S, Colombo C, Pirovano A, Marino E, Smeraldi E. A length polymorphism in the circadian clock gene *Per3* influences age at onset of bipolar disorder. *Neurosci Lett* 2008; **445**: 184–187.
- 56 Dijk DJ, Archer SN. *PERIOD3*, circadian phenotypes, and sleep homeostasis. *Sleep Med Rev* 2010; **14**: 151–160.
- 57 Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. *Bipolar Disord* 2006; **8**: 625–639.
- 58 Statham DJ, Heath AC, Madden PA, Bucholz KK, Bierut L, Dinwiddie SH et al. Suicidal behaviour: an epidemiological and genetic study. *Psychol Med* 1998; **28**: 839–855.
- 59 Fu Q, Heath AC, Bucholz KK, Nelson EC, Glowinski AL, Goldberg J et al. A twin study of genetic and environmental influences on suicidality in men. *Psychol Med* 2002; **32**: 11–24.
- 60 Schulze TG, Hedeker D, Zandi P, Rietschel M, McMahon FJ. What is familial about familial bipolar disorder? Resemblance among relatives across a broad spectrum of phenotypic characteristics. *Arch Gen Psychiatry* 2006; **63**: 1368–1376.
- 61 Valtonen H, Suominen K, Partonen T, Ostamo A, Lonnqvist J. Time patterns of attempted suicide. *J Affect Disord* 2006; **90**: 201–207.
- 62 Preti A, Miotto P. Diurnal variations in suicide by age and gender in Italy. *J Affect Disord* 2001; **65**: 253–261.
- 63 Christodoulou C, Douzenis A, Papadopoulos FC, Papadopoulou A, Bouras G, Gournellis R et al. Suicide and seasonality. *Acta Psychiatr Scand* 2012; **125**: 127–146.
- 64 Sequeira A, Morgan L, Walsh DM, Cartagena PM, Choudary P, Li J et al. Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. *PLoS One* 2012; **7**: e35367.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies the paper on the Translational Psychiatry website (<http://www.nature.com/tp>)